Publisert 25.09.2019

Board Meeting No 6 2019

Board Meeting No 6. September 25th 2019

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.